ES2044829T1 - Una composicion para el tratamiento in vivo de da\os en los tejidos producidos por isquemia u otra disfuncion proveniente de oxidacion. - Google Patents

Una composicion para el tratamiento in vivo de da\os en los tejidos producidos por isquemia u otra disfuncion proveniente de oxidacion.

Info

Publication number
ES2044829T1
ES2044829T1 ES90915877T ES90915877T ES2044829T1 ES 2044829 T1 ES2044829 T1 ES 2044829T1 ES 90915877 T ES90915877 T ES 90915877T ES 90915877 T ES90915877 T ES 90915877T ES 2044829 T1 ES2044829 T1 ES 2044829T1
Authority
ES
Spain
Prior art keywords
spin
trapping
administration
treatment
oxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES90915877T
Other languages
English (en)
Other versions
ES2044829T3 (es
Inventor
John M Carney
Robert A Floyd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
University of Kentucky Research Foundation
Original Assignee
Oklahoma Medical Research Foundation
University of Kentucky Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/422,651 external-priority patent/US5025032A/en
Application filed by Oklahoma Medical Research Foundation, University of Kentucky Research Foundation filed Critical Oklahoma Medical Research Foundation
Publication of ES2044829T1 publication Critical patent/ES2044829T1/es
Application granted granted Critical
Publication of ES2044829T3 publication Critical patent/ES2044829T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE DESCRIBEN COMPOSICIONES CONTENIENDO COMO INGREDIENTE ACTIVO UN REACTIVO QUE ES ATRAPADO EN EL CENTRIFUGADO, PREFERENTEMENTE (ALFA)-FENIL BUTIL NITRONA (PNB), O SUS DERIVADOS QUE SON ATRAPADOS EN EL CENTRIFUGADO, EN UN PORTADOR FARMACEUTICO APROPIADO PARA LA ADMINISTRACION A UN PACIENTE, PARA EL TRATAMIENTO O PREVENCION DE SINTOMAS ASOCIADOS CON ATAQUES U OTROS DAÑOS ISQUEMICOS, ENVEJECIMIENTO U OTRAS CONDICIONES ASOCIADAS CON EL DAÑO OXIDATIVO A LOS TEJIDOS. PARA LA PREVENCION O TRATAMIENTO DEL DAÑO COMO RESULTADO DE LA ISQUEMIA, LAS COMPOSICIONES SE ADMINISTRAN ANTES O DURANTE LA ISQUEMIA EN UNA DOSIS EFICAZ, PARA PREVENIR O INVERTIR LA PREDISPOSICION DE LAS CELULAS AL DAÑO RESULTANTE DEL EMPOBRECIMIENTO DE ATP Y EL DAÑO DE LA GENERACION DE RADICAL LIBRE QUE SIGUE A LA REPERCUSION. EJEMPLOS DE ENFERMEDADES QUE PUEDEN SER TRATADAS INCLUYEN; ATAQUES, MENINGITIS, PERDIDA NEURONAL PROGRESIVA DEBIDO A LA ENFERMEDAD DE PARKINSON, DEMENCIA SENIL, DROGADICCION, ENFERMEDADES QUE APARECEN POR LAEXPOSICION A OXIGENO A GRAN PRESION O ENTORNOS CON OXIGENO ENRIQUECIDO, Y UNA HEMORRAGIA DEL TEJIDO NERVIOSO COMO RESULTADO DE UN TRAUMATISMO. PARA EL TRATAMIENTO DEL ENVEJECIMIENTO, LAS COMPOSICIONES SE ADMINISTRAN PREFERENTEMENTE UNA O DOS VECES AL DIA MEDIANTE ADMINISTRACION ORAL DURANTE UN PERIODO DE DOS SEMANAS. SE OBSERVA UNA SIGNIFICANTE REDUCCION DE PROTEINAS OXIDADAS Y RECUPERACION DE MEMORIA AL CABO DE SIETE DIAS DESPUES DEL COMIENZO DEL TRATAMIENTO.
ES90915877T 1989-10-17 1990-10-17 Metodo y composiciones para la inhibicion de alteraciones asociadas con las lesiones oxidativas de los tejidos. Expired - Lifetime ES2044829T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/422,651 US5025032A (en) 1989-10-17 1989-10-17 Phenyl butyl nitrone compositions and methods for treatment of oxidative tissue damage
US58917790A 1990-09-27 1990-09-27

Publications (2)

Publication Number Publication Date
ES2044829T1 true ES2044829T1 (es) 1994-01-16
ES2044829T3 ES2044829T3 (es) 1995-01-16

Family

ID=27025701

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90915877T Expired - Lifetime ES2044829T3 (es) 1989-10-17 1990-10-17 Metodo y composiciones para la inhibicion de alteraciones asociadas con las lesiones oxidativas de los tejidos.

Country Status (12)

Country Link
US (4) US5405874A (es)
EP (1) EP0496796B1 (es)
JP (5) JP2620413B2 (es)
KR (1) KR960008230B1 (es)
AT (1) ATE110565T1 (es)
AU (4) AU653921B2 (es)
CA (1) CA2069961C (es)
DE (1) DE69012138T2 (es)
DK (1) DK0496796T3 (es)
ES (1) ES2044829T3 (es)
HK (1) HK1007281A1 (es)
WO (1) WO1991005552A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2395803A1 (es) * 2011-08-01 2013-02-15 Consejo Superior De Investigaciones Científicas (Csic) - 80% Quinolilnitronas

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69012138T2 (de) * 1989-10-17 1995-04-06 Oklahoma Medical Research Foundation, Oklahoma, Okla. Verfahren und zubereitungen zur hemmung von mit oxidativer schädigung assoziierten krankheiten.
US5681845A (en) * 1989-10-17 1997-10-28 Oklahoma Medical Research Foundation DMPO spin trapping compositions and methods of use thereof
US20050107366A1 (en) * 1991-06-18 2005-05-19 Carney John M. Spin trapping pharmaceutical compositions and methods for use thereof
ATE209908T1 (de) * 1991-06-18 2001-12-15 Oklahoma Med Res Found RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN
US6002001A (en) 1991-06-18 1999-12-14 Oklahoma Medical Research Foundation Spin trapping pharmaceutical compositions and methods for use thereof
US5292746A (en) * 1991-09-12 1994-03-08 Merrell Dow Pharmaceuticals Inc. Cyclic nitrones, pharmaceutical compositions thereof and their use in treating shock
NZ244268A (en) * 1991-09-12 1994-09-27 Merrell Pharma Inc N-oxide quinoline derivatives and pharmaceutical compositions
JPH0656669A (ja) * 1992-06-11 1994-03-01 Asahi Breweries Ltd 活性酸素消去作用を持つプテリン誘導体製剤
JPH08505406A (ja) * 1993-10-25 1996-06-11 オゥクラホゥマ、メディカル、リサーチ、ファウンデイシャン 新規のリン含有スピン捕捉組成物
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
FR2731428B1 (fr) * 1995-03-06 1997-06-06 Centre Nat Rech Scient Derives phosphoryles de nitrones, leur procede de preparation et compositions les contenant
KR100512675B1 (ko) * 1995-09-11 2006-08-10 아벤티스 파마슈티칼스 인크. 사이클릭니트론및이를포함하는약제학적조성물
CA2235765C (en) * 1995-11-17 2006-04-04 David A. Becker Azulenyl nitrone spin trapping agents, methods of making and using same
AU725432B2 (en) * 1996-04-17 2000-10-12 Centaur Pharmaceuticals, Inc. Nitrone free radical trap treatment of dementia associated with AIDS virus (HIV-1) infection
EP0910370B1 (en) * 1996-04-23 2004-04-07 Centaur Pharmaceuticals, Inc. Compositions comprising a nitrone compound for use in treating uveitis
US5900227A (en) * 1996-06-17 1999-05-04 Oklahoma Medical Research Foundation Multicyclic nitrone spin trapping compositions
EP1021430A1 (en) * 1996-07-19 2000-07-26 Centaur Pharmaceuticals, Inc. Furan nitrone compounds
TW429241B (en) * 1996-09-26 2001-04-11 Sumitomo Pharma Nitrone derivatives
US6046232A (en) * 1997-10-17 2000-04-04 Centaur Pharmaceuticals, Inc. α-aryl-N-alkylnitrones and pharmaceutical compositions containing the same
US5998469A (en) * 1998-01-16 1999-12-07 Centaur Pharmaceuticals, Inc. Thioether furan nitrone compounds
DE69904018D1 (en) * 1998-01-16 2003-01-02 Centaur Pharmaceuticals Inc Thiophennitronderivate
DE69917643T2 (de) 1998-07-17 2004-10-07 Renovis Inc Alpha-(2-hydroxyphenyl)nitrone, diese enthaltenden pharmazeutische zubereitungen sowie deren verwendung zur behandlung von entzündungen
US6730700B2 (en) 1998-12-02 2004-05-04 Renovis, Inc. 3,4,5,-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same
UA66401C2 (en) 1998-12-02 2004-05-17 Sentor Pharmaceuticals Inc 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical composition containing the same
WO2000074672A1 (en) * 1999-06-09 2000-12-14 Department Of The Army, U.S. Government Method and compositions for treating and preventing retinal damage
CA2404291A1 (en) * 2000-03-30 2001-10-11 Oklahoma Medical Research Foundation Butylnitrone containing compositons for inhibition of cancer development
SE0001916D0 (sv) * 2000-05-23 2000-05-23 Astrazeneca Ab Novel formulation
WO2002065993A2 (en) 2001-01-08 2002-08-29 Centaur Pharmaceuticals, Inc. Use of aryl nitrone compounds in methods for treating neuropathic pain
US20030045461A1 (en) * 2001-09-06 2003-03-06 Jen-Chang Hsia Composition and methods of esterified nitroxides gated with carboxylic acids
FR2846968B1 (fr) 2002-11-08 2005-02-04 Salles Jean Pierre Nouveaux derives amphiphiles de l'alpha-c-phenyl-n-tert- butyl nitrone
US6762322B1 (en) * 2002-12-20 2004-07-13 Goodyear Tire & Rubber Company Preparation of nitrone derivatives
US20050059638A1 (en) * 2003-08-04 2005-03-17 Kelly Michael G. Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders
US20050182060A1 (en) * 2004-02-13 2005-08-18 Kelly Michael G. 2-Substituted and 4-substituted aryl nitrone compounds
US20060235370A1 (en) * 2005-04-04 2006-10-19 Oblong John E Method of regulating mammalian keratinous tissue
US7125934B1 (en) * 2005-06-28 2006-10-24 The Goodyear Tire & Rubber Company Functionalization of living rubbery polymers with nitrones
EP2054047B1 (en) * 2006-07-25 2014-12-17 Hough Ear Institute Methods for treating acute acoustic trauma
WO2009102808A2 (en) 2008-02-12 2009-08-20 Tosk, Incorporated Doxorubicin adjuvants to reduce toxicity and methods for using the same
WO2009110585A1 (ja) * 2008-03-07 2009-09-11 国立大学法人熊本大学 電子スピン共鳴測定用試料溶液及びその乾固物，並びにそれらを用いた測定方法
US8591146B2 (en) * 2009-04-20 2013-11-26 Volvo Construction Equipment Ab Integrated paving system and method
US9034926B2 (en) 2010-12-30 2015-05-19 Nicholas V. Perricone Topical nitrone spin trap compositions for psoriasis
US8986739B2 (en) 2011-02-28 2015-03-24 Nicholas V. Perricone Treatment of urinary incontinence using nitrone spin traps
DE102011088787A1 (de) 2011-12-16 2013-06-20 Evonik Industries Ag Siloxannitrone und deren Anwendung
WO2022169642A1 (en) * 2021-02-08 2022-08-11 Oklahoma Medical Research Foundation Okn-007 as a therapeutic agent for neurodegenerative diseases

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE273702C (es) *
US35112A (en) * 1862-04-29 Improvement in head-rests for car-seats
US35213A (en) * 1862-05-13 Improved hydrant
US3396027A (en) * 1964-05-13 1968-08-06 Eastman Kodak Co Method of noodling gelatin dispersions
US3365296A (en) 1964-05-18 1968-01-23 Gen Aniline & Film Corp Light-sensitive ultraviolet absorbing compounds and diazotype materials containing the same
US3296145A (en) * 1965-10-21 1967-01-03 Millmaster Onyx Corp Quaternary ammonium-tertiary amine oxide compositions
US3775122A (en) 1967-07-28 1973-11-27 American Can Co Image production using photosensitive compositions of nitrone which is heat developed
US3834073A (en) * 1971-05-03 1974-09-10 Scm Corp Phenyl nitrone derivatives useful as seed protectants
US3849934A (en) * 1971-05-03 1974-11-26 Scm Corp Alpha-aryl-n-lower alkyl nitrone-containing compositions useful as anti-fungal agents
US3767818A (en) 1971-05-03 1973-10-23 Scm Corp Phenyl nitrone containing compositions useful as anti microbial agents
GB1531278A (en) * 1975-12-15 1978-11-08 Shionogi & Co 9,10-dihydro-9,10-methanoanthracene n-oxide derivatives and the production thereof
GB1588417A (en) * 1977-03-15 1981-04-23 Agfa Gevaert Photoresist materials
US4224340A (en) * 1977-10-06 1980-09-23 William H. Rorer, Inc. Anti-inflammatory compositions containing α-phenyl-N-phenylnitrone compounds
US4197314A (en) * 1977-10-06 1980-04-08 William H. Rorer, Inc. Method of treating inflammation
US4214003A (en) * 1977-10-06 1980-07-22 William H. Rorer, Inc. Method of treatment
US4153722A (en) * 1977-10-06 1979-05-08 William H. Rorer, Inc. Method of treatment
US4870002A (en) * 1981-04-07 1989-09-26 The United States Of America As Represented By The Secretary Of The Air Force Method of prevention of oxidative injury to cells
AU1107888A (en) * 1986-12-29 1988-07-27 Pharmacia Ab Nitroxide compounds for the preparation of a pharmaceutical composition intended for the prophylaxis and treatment of ischemic cell damage
AU1362488A (en) * 1987-01-28 1988-08-24 Peter H. Proctor Topical composition and method for stimulating hair growth with stable free radicals
US5025032A (en) * 1989-10-17 1991-06-18 Oklahoma Medical Research Foundation Phenyl butyl nitrone compositions and methods for treatment of oxidative tissue damage
DE69012138T2 (de) * 1989-10-17 1995-04-06 Oklahoma Medical Research Foundation, Oklahoma, Okla. Verfahren und zubereitungen zur hemmung von mit oxidativer schädigung assoziierten krankheiten.
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2395803A1 (es) * 2011-08-01 2013-02-15 Consejo Superior De Investigaciones Científicas (Csic) - 80% Quinolilnitronas

Also Published As

Publication number Publication date
EP0496796B1 (en) 1994-08-31
AU8310198A (en) 1998-12-24
KR920702220A (ko) 1992-09-03
CA2069961C (en) 2000-05-02
KR960008230B1 (ko) 1996-06-21
AU6613390A (en) 1991-05-16
CA2069961A1 (en) 1991-04-18
DK0496796T3 (da) 1994-10-03
ES2044829T3 (es) 1995-01-16
AU710341B2 (en) 1999-09-16
JP2002179563A (ja) 2002-06-26
AU1131595A (en) 1995-03-23
JPH10259128A (ja) 1998-09-29
AU653921B2 (en) 1994-10-20
US6107315A (en) 2000-08-22
AU710342B2 (en) 1999-09-16
EP0496796A1 (en) 1992-08-05
JP2620413B2 (ja) 1997-06-11
DE69012138D1 (de) 1994-10-06
HK1007281A1 (en) 1999-04-09
US5681965A (en) 1997-10-28
ATE110565T1 (de) 1994-09-15
JPH05505792A (ja) 1993-08-26
JPH10259178A (ja) 1998-09-29
US5578617A (en) 1996-11-26
AU8310298A (en) 1998-10-22
JP2816326B2 (ja) 1998-10-27
WO1991005552A1 (en) 1991-05-02
JPH0925263A (ja) 1997-01-28
DE69012138T2 (de) 1995-04-06
US5405874A (en) 1995-04-11
AU692197B2 (en) 1998-06-04
JP2975587B2 (ja) 1999-11-10

Similar Documents

Publication Publication Date Title
ES2044829T1 (es) Una composicion para el tratamiento in vivo de da\os en los tejidos producidos por isquemia u otra disfuncion proveniente de oxidacion.
DE60043587D1 (de) Mittel für erkrankungen assoziert mit knochensubstanzverlust
CA2111836A1 (en) Spin-trapping pharmaceutical compositions and methods for use thereof
ES2191754T3 (es) Fenil-dihidrobenzofuranos.
DE69818286D1 (de) Pyridylverbindungen und diese enthaltende pharmazeutische zubereitungen
DE59610031D1 (de) Cyclohexyldihydrobenzofurane
IL85228A (en) 1-(4-hydroxy-3,5-di-tert.- butylbenzoyl) homopiperazine, various derivatives thereof, processes for the preparation of these and pharmaceutical compositions containing them
GR890100834A (en) Pyridine derivatives their production and use
DK393188D0 (da) Farmaceutisk praeparat til intranasal administrering
PT90308A (pt) Processo para a preparacao de composicoes farmaceuticas contendo azelastina com libertacao controlada da substancia activa
EG19302A (en) Compound with gastric acid inhibitory effect and process for its preparation
DK1115697T3 (da) Umættede hydroximsyrederivater som PARP-inhibitorer
EE04058B1 (et) Benso[c]kinolisiini derivaadid, nende valmistamine ja kasutamine 5a-reduktaasi inhibiitoritena
DK1231908T3 (da) Farmaceutisk præparat, der omfatter en NO-donorforbindelse samt anvendelse heraf
FI892685A0 (fi) Menetelmä uusien, sytostaattisesti vaikuttavien antrasykliinijohdannaisten valmistamiseksi
DK0486586T3 (da) Kynurensyrederivater, fremstilling deraf og farmaceutiske præparater, der indeholder dem
ATE414530T1 (de) Lactalbumin zur kurativen behandlung von magengeschwüren

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 496796

Country of ref document: ES